In recent decades, the treatment of cancer has shown great development in the fields of surgery, radiation therapy and the emergence of cytotoxic chemotherapy and targeted cancer therapies (including monoclonal antibodies, tyrosine-kinase inhibitors and angiogenesis inhibitors). Consequently, there has been an increase in survival of patients with cancer, making cardiovascular complications related to chemotherapy be more carefully taken into consideration by cardiologists and oncologists. The most frequent clinical manifestation of cardiotoxicity is symptomatic or asymptomatic ventricular dysfunction that can progress to heart failure1. Ventricular dysfunction can occur not only after conventional chemotherapy with anthracyclines, but with the new antitumor agents, such as trastuzumab. Several studies have shown that screening for cardiotoxicity by assessing the ejection fraction may be inadequate to detect subclinical disease2. It is known that the time of implementation of cardiovascular therapy is an important prognostic factor in heart function recovery and to prevent heart failure development3. Thus, several biomarkers have been studied in an attempt at early detection of cardiotoxicity, particularly troponin, BNP and microRNAs4,5. However, the optimal time of collection, or an ideal population to be submitted to this screening is yet to be determined. In addition, more sensitive methods for the assessment of cardiac structure and function, such as magnetic resonance imaging and strain echocardiography seem to detect the subclinical forms of the disease2. Some medications commonly used in the management of heart failure have shown a beneficial effect on chemotherapy-related cardiotoxicity. The use of angiotensin-converting enzyme inhibitors in patients with troponin increase during chemotherapy can be an effective tool to prevent left ventricular dysfunction and late cardiovascular events6. However, there are no large studies that evaluated the effect of these medications on anticancer therapy efficacy. In the treatment of cardiotoxicity associated with the use of chemotherapeutic agents, beta-blockers, enzyme inhibitors and angiotensin-converting enzyme inhibitors seem to be effective. However, early treatment of ventricular dysfunction is important, considering the correlation between the time of start of ventricular dysfunction treatment and cardiac function recovery1. The HER2 gene amplification and/or overexpression of its protein occurs in approximately 20% of breast cancers and is associated with a worse prognosis7. New chemotherapeutic agents, targeted at the HER2 receptor and its action pathway, have revolutionized the treatment of this type of cancer8. Trastuzumab, a humanized monoclonal antibody, was the first targeted therapy against the HER2 pathway and its use has changed the natural history of HER2+ breast cancer, resulting in improved survival similar to HER2- breast cancers. Thus, trastuzumab has become the key point in the treatment of HER2 + breast cancer. However, despite the outstanding benefits in survival related to anti-HER2 treatment, a significant increase in drug-related cardiac toxicity has been observed9, with several cardiac dysfunction events reported in clinical studies with the use of trastuzumab. Although cardiac toxicity induced by anti-HER2 therapy is not completely understood, preclinical studies have demonstrated an important role of HER2 signaling pathway in cardiac physiology, since both HER2 receptors and its ligands are expressed in cardiomyocytes. Despite the benefits offered by anti-HER therapy, there is justified concern about the potential adverse cardiac events and studies are needed to assess ways of early detection of this toxicity, as well as the best way of handling it, as the pathways of toxicity and therapeutics10 may be superimposed. It is believed that diastolic dysfunction may precede the onset of left ventricular systolic dysfunction11. In this issue, Dores et al12 studied 51 women with HER2 + breast cancer for five months to assess the occurrence of early cardiotoxicity. Although they found no symptomatic heart failure, the authors showed that as early as the third month of treatment, there were differences in diastolic parameters after the use of trastuzumab. The authors found a statistically significant difference in the E/e' ratio from the beginning to the third month of follow-up related to a reduction in myocardial velocity, as assessed by tissue Doppler. More than half of patients (57.9%) showed a decrease in ejection fraction, but only one had a decrease below 55%. With the development of cardio-oncology and the constant advent of new chemotherapeutic agents, surveillance studies and the search for early markers of cardiac abnormalities in cancer patients is of great importance for the adequate management of these patients. Editorial under the responsibility of Cardiosource in Portuguese. http://cientifico.cardiol.br/cardiosource2/default.asp
Read full abstract
Oct 30, 2014
F Alite + 3
Open Access
